Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm …
…, A Meyer, P Mustonen, URauch-Kroehnert… - European heart …, 2020 - academic.oup.com
Aims To investigate the efficacy and safety of early transition from hospital to ambulatory
treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban. Methods and …
treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban. Methods and …
Micro–RNA-126 reduces the blood thrombogenicity in diabetes mellitus via targeting of tissue factor
…,U Landmesser, URauch-Kroehnert- … , and vascular biology, 2016 - Am Heart Assoc
Objective— Diabetes mellitus involves vascular inflammatory processes and is a main
contributor to cardiovascular mortality. Notably, heightened levels of circulating tissue factor (TF) …
contributor to cardiovascular mortality. Notably, heightened levels of circulating tissue factor (TF) …
Differential immunological signature at the culprit site distinguishes acute coronary syndrome with intact from acute coronary syndrome with ruptured fibrous cap …
…, G Fröhlich, URauch-Kröhnert… - European Heart …, 2020 - academic.oup.com
Aims Acute coronary syndromes with intact fibrous cap (IFC-ACS), ie caused by coronary
plaque erosion, account for approximately one-third of ACS. However, the underlying …
plaque erosion, account for approximately one-third of ACS. However, the underlying …
Survival and quality of life after early discharge in low-risk pulmonary embolism
…, P Mustonen, URauch-Kroehnert… - European …, 2021 - Eur Respiratory Soc
Introduction Early discharge of patients with acute low-risk pulmonary embolism requires
validation by prospective trials with clinical and quality-of-life outcomes. Methods The …
validation by prospective trials with clinical and quality-of-life outcomes. Methods The …
PCSK9 inhibitors and cardiovascular outcomes
…, A Hassanein, J Friebel, URauch-Kröhnert- Expert Opinion on …, 2020 - Taylor & Francis
Introduction: Dyslipidemia, particularly elevated low-density lipoprotein cholesterol (LDL-C),
is a key risk factor for atherosclerotic cardiovascular disease (ASCVD), and lipid-lowering …
is a key risk factor for atherosclerotic cardiovascular disease (ASCVD), and lipid-lowering …
[HTML][HTML]Impact of real-time angiographic co-registered optical coherence tomography on percutaneous coronary intervention: the OPTICO-integration II trial
…, A Lauten, G Froehlich, URauch-Kroehnert… - Clinical Research in …, 2021 - Springer
Aims Longitudinal geographic mismatch (LGM) as well as edge dissections are associated
with an increased risk of adverse events after percutaneous coronary intervention (PCI). …
with an increased risk of adverse events after percutaneous coronary intervention (PCI). …
Real‐time optical coherence tomography coregistration with angiography in percutaneous coronary intervention–impact on physician decision‐making: The OPTICO …
…, L Lübking, URauch‐Kröhnert… - Catheterization and …, 2018 - Wiley Online Library
目的Intracoronary optical coherence tomography (OCT) imaging allows for high‐resolution
characterization of coronary lesions. Difficulties in matching cross‐sectional OCT‐images …
characterization of coronary lesions. Difficulties in matching cross‐sectional OCT‐images …
Adenine Nucleotide Translocase 1 Expression Modulates the Immune Response in Ischemic Hearts
F Yergöz, J Friebel, N Kränkel, URauch-Kroehnert… - Cells, 2021 - mdpi.com
Adenine nucleotide translocase 1 (ANT1) transfers ATP and ADP over the mitochondrial inner
membrane and thus supplies the cell with energy. This study analyzed the role of ANT1 in …
membrane and thus supplies the cell with energy. This study analyzed the role of ANT1 in …
[PDF][PDF]Disease Severity in Moderate-to-Severe COVID-19 Is Associated With Platelet Hyperreactivity and Innate Immune Activation
…, A Haghikia, N Kränkel, URauch-Kröhnert- Frontiers in …, 2022 - frontiersin.org
Background: Hemostasis and inflammation are both dysregulated in patients with moderate-to-severe
coronavirus disease 2019 (COVID-19). Yet, both processes can also be disturbed …
coronavirus disease 2019 (COVID-19). Yet, both processes can also be disturbed …
[HTML][HTML]Antikoagulation bei „coronavirus disease 2019 “(COVID-19)–Gesichertes und Kontroverses
URauch-Kröhnert, H Riess - Der Internist, 2022 - Springer
Die Infektion mit dem „severe acute respiratory syndrome coronavirus 2“ (SARS-CoV-2) ist
mit einem hohen Risiko mikrovaskulärer Immunthrombosen sowie symptomatischer und …
mit einem hohen Risiko mikrovaskulärer Immunthrombosen sowie symptomatischer und …